Abstract
Enterobacter cloacae complex has been increasingly recognized as a nosocomial pathogen representing the third major Enterobacteriaceae species involved with infections. This study aims to evaluate virulence and antimicrobial susceptibility of subpopulations generated from macrocolonies of NDM-1 producing Enterobacter hormaechei clinical isolates. Biofilm was quantified using crystal violet method and fimbrial genes were investigated by PCR. Susceptibility of antimicrobials, alone and combined, was determined by minimum inhibitory concentration and checkerboard assays, respectively. Virulence and efficacy of antimicrobials were evaluated in Galleria mellonella larvae. Importantly, we verified that some subpopulations that originate from the same macrocolony present different biofilm production ability and distinct susceptibility to meropenem due to the loss of blaNDM-1 encoding plasmid. A more in-depth study was performed with the 798 macrocolony subpopulations. Type 3 fimbriae were straightly related with biofilm production; however, virulence in larvae was not statistically different among subpopulations. Triple combination with meropenem–rifampicin–polymyxin B showed in vitro synergistic effect against all subpopulations; while in vivo this treatment showed different efficacy rates for 798-1S and 798-4S subpopulations. The ability of multidrug resistant E. hormaechei isolates in generating bacterial subpopulations presenting different susceptible and virulence mechanisms are worrisome and may explain why these infections are hardly overcome.
Highlights
The Enterobacteriaceae family is composed by many bacteria, including Escherichia coli, Klebsiella spp., and Enterobacter spp., responsible for community-associated as well as healthcare-associated infections [1,2,3]
Subpopulations originated from the same macrocolony showed differences in meropenem susceptibility; some were susceptible (MIC < 2 μg/mL) and others resistant (MIC > 8 μg/mL)
Presence of blaNDM-1 gene was evaluated in all subpopulations and it was not detected in susceptible subpopulations, confirming that the loss of this gene restored meropenem susceptibility
Summary
The Enterobacteriaceae family is composed by many bacteria, including Escherichia coli, Klebsiella spp., and Enterobacter spp., responsible for community-associated as well as healthcare-associated infections [1,2,3]. Carbapenem resistance constitutes a global public-healthcare problem associated with a high mortality. Studies have reported that combination therapy with two or more antimicrobials is associated with a better outcome than monotherapy [13,14,15]. Carbapenem-containing combinations are used in addition to polymyxin in clinical settings. Studies suggest an additional benefit of including a carbapenem in combination regimens, especially in the context of strains with low minimum inhibitory concentrations (MICs) against carbapenems [15,17]. Rifampicin is considered for inclusion in combination regimens because of its ability to penetrate intracellular sites and biofilms, which could be important in the treatment of CPE infections involving biofilm [16]. Antimicrobials with reliable activity against CPE (> 85% of strains susceptible) typically include tigecycline, polymyxin B and colistin, and fosfomycin [17]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
